Anticardiolipin antibodies after kidney transplantation in patients without connective tissue disease

Grandtnerova, B.; Gregová, H; Móciková, Heidi; Zacharová, M; Zarnovicanová, Mária

doi:10.1016/s0041-1345(98)01513-9

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They comprised 152 aPL-ve and 57 aPL+ve recipients for the effect size of this outcome [9,12,16]; the pooled prevalence of allograft malfunction was not dissimilar in aPL-ve and positive recipients (32.2% vs 40.3%) (Figure 3E). Two articles from the same group evaluated the relationship between different aPL and allograft duration: these include 137 aPL negative and 128 positive recipients for the effect size of this outcome [19,29]; graft duration was much shorter in aPL+ve than aPL-ve recipients (p=0.001)(Figure 3F).…”

Section: Allograft Malfunction and Durationmentioning

confidence: 98%

See 1 more Smart Citation

Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis

Merashli

Bucci

Gentile

et al. 2019

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Objective. To evaluate the effect of antiphospholipid antibodies (aPL) on renal allograft outcome after kidney transplantation. Methods. A systematic search of EMBASE and PubMed databases from inception to July 2018 was run according to PRISMA guidelines; Peto's odds ratio (OR) for rare events was used for the meta-analysis. Results. Our inclusion/exclusion criteria were met by 22 cohort studies having different outcomes: allograft thrombosis (n=9) and thromboprophylaxis (n=3), allograft loss from any cause (n=9), allograft malfunction (n=3), duration (n=2), glomerular filtration rate at 1 year (n=3) and allograft rejection (n=5). The pooled prevalence of allograft thrombosis and of thrombotic microangiopathy was greater in aPL+ve than negative recipients (10.4% vs 1.7%,

show abstract

Section: Allograft Malfunction and Durationmentioning

confidence: 98%

“…Allograft malfunction was variably defined as transplant duration (10), worsening renal function (creatinine, proteinuria, eGFR) (9,12,26,23) and requirement for transient haemodialysis sessions post allograft transplant (19,29). These were combined together in our result section dealing with malfunction.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis

Merashli

Bucci

Gentile

et al. 2019

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

show abstract

“…Renal allografts that function beyond the immediate post-transplant period in aPL-positive patients may still be at risk for aPL induced damage. 6 This study, comprising 20 patients, tested serial blood samples for IgG and IgM aCL, collected post-transplant with at least three month intervals. Eleven (55%) of the patients were aCL positive in at least two of their serum specimens.…”

Section: Post-transplant Effect Of Aclmentioning

confidence: 99%

Antiphospholipid antibodies and renal transplantation: a risk assessment

McIntyre

Wagenknecht

2003

Lupus

View full text Add to dashboard Cite

Data from 110 transplanted patients show that the presence of antiphospholipid antibodies (aPL) at the time of transplantation is an important risk factor for early renal allograft failure. Sera were tested for IgG, IgM and IgA to CL, PS, PE and PC. Haemodialysis patients had a significantly higher incidence of aPL compared to patients who did not receive haemodialysis (P = 0.0171). aPL-positive ESRD patients on peritoneal dialysis (CAPD) or who had never received haemodialysis were at maximal risk; 100% failure (P = 0.0022). aPL-positive patients receiving haemodialysis were not at such risk. Biopsy findings from the failed kidneys show abundant fibrin deposition in the microvasculature. Serial blood samples from transplanted patients showed aPL titres to decrease immediately after transplant and increase after removal of the failed graft, indicating that aPL specifically target the allografts. To confirm this, we were able to isolate aPL from a failed graft after transplant nephrectomy. Ninety-seven per cent of the aPL-positive patients' historic pre-transplant serum samples demonstrated the presence of the same aPL specificity detected in the final crossmatch sera. The exposure to heparin during haemodialysis suggested to us that heparin reduces the risk of clotting in aPL positive transplant candidates. To lessen the risk of graft loss in aPL positive kidney transplant patients (including CAPD), subcutaneous heparin was administered peri- and post-operatively. To date, none of the heparin-treated aPL-positive transplanted patients suffered an early graft loss. Further, they experienced fewer rejection episodes requiring biopsy and thus are prescribed less steroid therapy than patients not treated with heparin.

show abstract

Transplantation of Solid Organs, Tissues, and Prosthetic Devices in Patients with Antiphospholipid Antibodies

Wagenknecht

McIntyre

Hughes Syndrome

View full text Add to dashboard Cite

Anticardiolipin antibodies after kidney transplantation in patients without connective tissue disease

Cited by 6 publications

References 10 publications

Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis

Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis

Antiphospholipid antibodies and renal transplantation: a risk assessment

Transplantation of Solid Organs, Tissues, and Prosthetic Devices in Patients with Antiphospholipid Antibodies

Contact Info

Product

Resources

About